메뉴 건너뛰기




Volumn 55, Issue 1422, 2013, Pages 62-63

Dabrafenib (Tafinlar) and Trametinib (Mekinist) for metastatic melanoma
[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DABRAFENIB; DACARBAZINE; IPILIMUMAB; MEKINIST; MITOGEN ACTIVATED PROTEIN KINASE 1; PACLITAXEL; TAFINLAR; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB;

EID: 84881037448     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter
Times cited : (7)

References (8)
  • 1
    • 82255170781 scopus 로고    scopus 로고
    • Vemurafenib (Zelboraf) for metastatic melanoma
    • Vemurafenib (Zelboraf) for metastatic melanoma. Med Lett Drugs Ther 2011; 53:77.
    • (2011) Med Lett Drugs Ther , vol.53 , pp. 77
  • 2
    • 80051836319 scopus 로고    scopus 로고
    • Ipilimumab (Yervoy) for metastatic melanoma
    • Ipilimumab (Yervoy) for metastatic melanoma. Med Lett Drugs Ther 2011; 53:51.
    • (2011) Med Lett Drugs Ther , vol.53 , pp. 51
  • 3
    • 84868224906 scopus 로고    scopus 로고
    • Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
    • KT Flaherty et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367:1694.
    • (2012) N Engl J Med , vol.367 , pp. 1694
    • Flaherty, K.T.1
  • 4
    • 84864285704 scopus 로고    scopus 로고
    • Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial
    • A Hauschild et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380:358.
    • (2012) Lancet , vol.380 , pp. 358
    • Hauschild, A.1
  • 5
    • 84874777853 scopus 로고    scopus 로고
    • Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor
    • KB Kim et al. Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2013; 31:482.
    • (2013) J Clin Oncol , vol.31 , pp. 482
    • Kim, K.B.1
  • 6
    • 84863673204 scopus 로고    scopus 로고
    • Improved survival with MEK inhibition in BRAF-mutated melanoma
    • KT Flaherty et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367:107.
    • (2012) N Engl J Med , vol.367 , pp. 107
    • Flaherty, K.T.1
  • 7
    • 84879023696 scopus 로고    scopus 로고
    • Inhibitors and inducers of CYP enzymes and P-glycoprotein
    • Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2013; 55:e44.
    • (2013) Med Lett Drugs Ther , vol.55
  • 8
    • 84878212424 scopus 로고    scopus 로고
    • Source: $ource® Monthly (Selected from FDB MedKnowledge™) July 5, 2013. Reprinted with permission by FDB, Inc. All rights reserved. ©2013, Actual retail prices may be higher
    • Wholesale acquisition cost. Source: $ource® Monthly (Selected from FDB MedKnowledge™) July 5, 2013. Reprinted with permission by FDB, Inc. All rights reserved. ©2013. www.fdbhealth.com/policies/drug-pricing-policy. Actual retail prices may be higher.
    • Wholesale acquisition cost


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.